




PHARMACEUTICAL 2019

iBio Inc.
Rank 237 of 363





PHARMACEUTICAL 2019

iBio Inc.
Rank 237 of 363



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 154% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 3.4% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	16,285
Cost of Goods Sold	0
Intangible Assets	1,620
Liabilities, Current	2,035
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	24,884
Other Net Income	-1,881
Other Revenues	444
Property and Equipment	25,152
Research and Development	3,986
Selling, General and Administrative Expense	10,685

Output Variable	Value in 1000 USD
Assets	43,083
Liabilities	26,919
Expenses	14,671
Revenues	444
Stockholders Equity	16,164
Net Income	-16,108
Comprehensive Net Income	-16,108
Economic Capital Ratio	33%